ATE556720T1 - Verfahren und zusammensetzungen zur rnai vermittelten inhibierung der genexpression in säugetieren - Google Patents

Verfahren und zusammensetzungen zur rnai vermittelten inhibierung der genexpression in säugetieren

Info

Publication number
ATE556720T1
ATE556720T1 AT02761123T AT02761123T ATE556720T1 AT E556720 T1 ATE556720 T1 AT E556720T1 AT 02761123 T AT02761123 T AT 02761123T AT 02761123 T AT02761123 T AT 02761123T AT E556720 T1 ATE556720 T1 AT E556720T1
Authority
AT
Austria
Prior art keywords
methods
compositions
mammals
rnai
gene expression
Prior art date
Application number
AT02761123T
Other languages
German (de)
English (en)
Inventor
Mark Kay
Anton Mccaffrey
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE556720T1 publication Critical patent/ATE556720T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
AT02761123T 2001-07-23 2002-07-19 Verfahren und zusammensetzungen zur rnai vermittelten inhibierung der genexpression in säugetieren ATE556720T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30741101P 2001-07-23 2001-07-23
US36066402P 2002-02-27 2002-02-27
PCT/US2002/022869 WO2003010180A1 (en) 2001-07-23 2002-07-19 Methods and compositions for rnai mediated inhibition of gene expression in mammals

Publications (1)

Publication Number Publication Date
ATE556720T1 true ATE556720T1 (de) 2012-05-15

Family

ID=26975733

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02761123T ATE556720T1 (de) 2001-07-23 2002-07-19 Verfahren und zusammensetzungen zur rnai vermittelten inhibierung der genexpression in säugetieren

Country Status (9)

Country Link
US (3) US20030153519A1 (enExample)
EP (2) EP1409506B1 (enExample)
JP (4) JP2005508306A (enExample)
AT (1) ATE556720T1 (enExample)
CA (2) CA2936534C (enExample)
DK (2) DK2280070T3 (enExample)
ES (2) ES2386775T3 (enExample)
PT (1) PT2280070E (enExample)
WO (1) WO2003010180A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143204A1 (en) * 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
US20050222075A1 (en) * 1998-09-14 2005-10-06 Hans Herweijer Process for delivering nucleic acids to cardiac tissue
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
BR0009884A (pt) * 1999-04-21 2002-01-08 American Home Prod Processos e composições para a inibição da função das sequências de polinucleotìdeos
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
US10590418B2 (en) * 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
WO2003010180A1 (en) 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
US7101995B2 (en) * 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
CN1628179B (zh) 2001-09-25 2011-04-20 肿瘤疗法科学股份有限公司 肝细胞癌的检测
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP2924116B1 (en) 2002-02-01 2018-05-02 Life Technologies Corporation Double-stranded oligonucleotides
WO2003087367A2 (en) * 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US20030228691A1 (en) * 2002-05-17 2003-12-11 Lewis David L. Processes for inhibiting gene expression using polynucleotides
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
ES2322145T3 (es) 2002-07-26 2009-06-17 Novartis Vaccines And Diagnostics, Inc. Moleculas pequeñas modificadas de adn inerferente y procedimiento de uso.
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
EP2112229A3 (en) 2002-11-25 2009-12-02 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
PT1897548E (pt) * 2003-02-28 2013-11-19 Univ Johns Hopkins Regulação de células t
EP1599586B9 (en) * 2003-02-28 2012-03-14 Oncotherapy Science, Inc. Rna-interference for znfn3a1-gene as a method for inhibiting cancer cell growth
US7750144B2 (en) * 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
EP1636364A2 (en) * 2003-06-06 2006-03-22 Senesco Technologies, Inc. INHIBITION OF APOPTOSIS-SPECIFIC ELF-5A ( EIF-5A1) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS
WO2005026322A2 (en) * 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
TWI350373B (en) 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
WO2005085443A2 (en) * 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
US20050233994A1 (en) * 2004-04-16 2005-10-20 Ajamete Kaykas Methods and vectors for expressing siRNA
WO2005118640A2 (en) * 2004-04-20 2005-12-15 University Of Utah Research Foundation A h+-gated ion channel
US7924288B2 (en) * 2004-06-22 2011-04-12 Nikon Corporation Image processing device emphasizing on texture, image processing program, electronic camera, and image processing method
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
KR20070062515A (ko) * 2004-08-11 2007-06-15 리셉터 바이오로직스 인크 가스트린-특이적 간섭 ｒｎａ
WO2006031901A2 (en) 2004-09-10 2006-03-23 Somagenics, Inc. SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
EP1796732B1 (en) * 2004-10-01 2013-10-30 Novartis Vaccines and Diagnostics, Inc. Modified small interfering rna molecules and methods of use
US7790693B2 (en) 2004-12-02 2010-09-07 University Of Massachusetts Glucose-transport related genes, polypeptides, and methods of use thereof
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
EP1838875A4 (en) * 2004-12-30 2010-08-25 Todd M Hauser COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION USING SELF-PROTECTED OLIGONUCLEOTIDES
CN101111269A (zh) * 2005-01-28 2008-01-23 协和发酵工业株式会社 抑制靶基因表达的组合物
CA2599337A1 (en) 2005-02-28 2006-09-08 Oncotherapy Science, Inc. Breast cancer related gene znfn3a1
EP1714970A1 (en) * 2005-04-22 2006-10-25 Universität des Saarlandes Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
US7723314B1 (en) 2005-10-28 2010-05-25 Transderm, Inc. Methods and compositions for treating pachyonychia congenita
EP1970078A4 (en) 2006-01-11 2010-11-17 Kyowa Hakko Kirin Co Ltd COMPOSITION INHIBITING THE EXPRESSION OF A TARGET GENE OF THE OCULAR GLOBE AND REMEDY FOR OCULAR GLOBE DISEASE
US9150882B2 (en) * 2006-01-31 2015-10-06 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
JP4752912B2 (ja) * 2006-02-27 2011-08-17 株式会社ニコン 画像の質感を補正する画像処理装置、画像処理プログラム、画像処理方法、および電子カメラ
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
EP2236623A1 (en) 2006-06-05 2010-10-06 Cancer Care Ontario Assessment of risk for colorectal cancer
PT2029746E (pt) * 2006-06-12 2012-10-15 Exegenics Inc D B A Opko Health Inc Composições e métodos para a inibição do sirna de angiogenese
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
WO2008106785A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
US8354223B2 (en) 2007-06-14 2013-01-15 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3
US20090087431A1 (en) * 2007-07-02 2009-04-02 Wyeth Methods of treating bone disorders with modulators of axl
US8309791B2 (en) * 2008-07-16 2012-11-13 Recombinectics, Inc. Method for producing a transgenic pig using a hyper-methylated transposon
EP2319519B1 (en) 2008-08-01 2016-01-27 Kyowa Hakko Kirin Co., Ltd. Composition for inhibiting expression of target gene
SG171952A1 (en) 2008-12-04 2011-07-28 Opko Ophthalmics Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
WO2011008730A2 (en) 2009-07-13 2011-01-20 Somagenics Inc. Chemical modification of small hairpin rnas for inhibition of gene expression
EP2666856A4 (en) 2011-01-19 2015-01-14 Kyowa Hakko Kirin Co Ltd COMPOSITION TO INHIBIT TARGET EXPRESSION
EP2704688B1 (en) 2011-05-05 2019-07-10 Matinas BioPharma Nanotechnologies, Inc. Cochleate compositions and methods of making and using same
US9913907B2 (en) 2012-07-16 2018-03-13 Kyowa Hakko Kirin Co., Ltd. RNAi pharmaceutical composition for suppressing expression of KRAS gene
AU2013308519A1 (en) * 2012-08-31 2015-04-09 The General Hospital Corporation Biotin complexes for treatment and diagnosis of Alzheimer's disease
CN104342453A (zh) 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
US9545417B2 (en) 2014-05-01 2017-01-17 The Johns Hopkins University Methods of inhibiting cancer stem cells with HMGA1 inhibitors
CN106794194A (zh) 2014-06-30 2017-05-31 中央研究院 用于癌症治疗的介白素‑17受体b（il‑17rb）及其配体il‑17b之拮抗剂
US20170216363A1 (en) 2014-08-07 2017-08-03 The Johns Hopkins University Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
WO2016025629A1 (en) 2014-08-12 2016-02-18 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
WO2016037157A2 (en) 2014-09-05 2016-03-10 The Johns Hopkins University Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
EA202091057A3 (ru) 2015-05-18 2021-03-31 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити Способы и композиции для лечения нарушений, ассоциированных со старением
MX2018002090A (es) 2015-08-24 2018-09-12 Halo Bio Rnai Therapeutics Inc Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
BR112019006110A2 (pt) 2016-09-28 2019-09-10 Blade Therapeutics Inc moduladores de calpaína e usos terapêuticos dos mesmos
US12031161B2 (en) 2020-10-09 2024-07-09 University Of Massachusetts Targeting Nrip1 to alleviate metabolic disease

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2425745C (en) 1989-03-21 2005-03-29 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
CA2038839A1 (en) * 1991-03-22 1992-09-23 Jiang J. Liu Method for detection of viral rna
ES2040615B1 (es) * 1991-05-27 1994-05-16 Nebrda Fernando Javi Bartolome Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis.
US6030954A (en) * 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
WO1994018156A1 (en) * 1993-02-01 1994-08-18 University Of Iowa Research Foundation Quartenary amine surfactants and methods of using same in isolation of rna
US5985847A (en) * 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
EP0759979A4 (en) * 1994-05-10 1999-10-20 Gen Hospital Corp THE ANTISENSE INHIBITION OF HEPATITIS C VIRUS
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5981279A (en) * 1995-11-09 1999-11-09 Allegheny University Of The Health Sciences Compositions and methods to regulate calmodulin gene expression, and uses thereof for influencing cell growth and differentiation
JP4033502B2 (ja) 1996-02-08 2008-01-16 アンジェスＭｇ株式会社 リボザイム、リポソーム製剤及びその用途
AU2542097A (en) * 1996-03-26 1997-10-17 Lynx Therapeutics, Inc. Oligonucleotide treatments and compositions for human melanoma
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
ATE232399T1 (de) 1997-04-04 2003-02-15 Max Planck Gesellschaft Verfahren zur modulierung des wachstums kollateraler arterien und / oder anderer arterien aus bestehenden arteriolen verbindungen
US5948902A (en) 1997-11-20 1999-09-07 South Alabama Medical Science Foundation Antisense oligonucleotides to human serine/threonine protein phosphatase genes
US5957978A (en) 1997-12-22 1999-09-28 Hansa Medical Products, Inc. Valved fenestrated tracheotomy tube
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
KR101085210B1 (ko) 1998-03-20 2011-11-21 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 유전자 발현 조절방법
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
BR0009884A (pt) * 1999-04-21 2002-01-08 American Home Prod Processos e composições para a inibição da função das sequências de polinucleotìdeos
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
WO2001032223A1 (en) 1999-11-05 2001-05-10 Mirus Corporation Intravascular delivery of nucleic acid
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
EP1272629A4 (en) 2000-03-17 2004-12-22 Benitec Australia Ltd gene silencing
KR20080023768A (ko) * 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
US20020132788A1 (en) * 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
CZ302719B6 (cs) 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
DE10100588A1 (de) 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US7000102B2 (en) 2001-06-29 2006-02-14 Intel Corporation Platform and method for supporting hibernate operations
CA2921821A1 (en) 2001-07-12 2003-01-23 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
WO2003010180A1 (en) 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
GB2397062B (en) 2002-02-20 2005-06-15 Sirna Therapeutics Inc RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)

Also Published As

Publication number Publication date
EP1409506A4 (en) 2004-11-17
JP6247355B2 (ja) 2017-12-13
EP1409506B1 (en) 2012-05-09
EP1409506A1 (en) 2004-04-21
HK1065562A1 (en) 2005-02-25
PT2280070E (pt) 2015-10-29
EP2280070B1 (en) 2015-05-20
CA2936534C (en) 2021-01-26
CA2936534A1 (en) 2003-02-06
US20130312126A1 (en) 2013-11-21
CA2454183C (en) 2016-09-06
US20200246370A1 (en) 2020-08-06
DK1409506T3 (da) 2012-08-06
DK2280070T3 (en) 2015-08-24
JP2005508306A (ja) 2005-03-31
JP2017008084A (ja) 2017-01-12
US10517887B2 (en) 2019-12-31
JP2015044809A (ja) 2015-03-12
WO2003010180A1 (en) 2003-02-06
JP2011093906A (ja) 2011-05-12
JP6055164B2 (ja) 2016-12-27
ES2546829T3 (es) 2015-09-29
EP2280070A1 (en) 2011-02-02
US20030153519A1 (en) 2003-08-14
ES2386775T3 (es) 2012-08-30
CA2454183A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
ATE556720T1 (de) Verfahren und zusammensetzungen zur rnai vermittelten inhibierung der genexpression in säugetieren
MX2022009280A (es) Vacunas de arn contra el coronavirus.
ATE550025T1 (de) Behandlung neurodegenerativer erkrankungen mittels intrakranialer freisetzung von small- interfering-rna (sirna)
NZ543467A (en) The severe acute respiratory syndrome coronavirus
DE60113805D1 (de) Intratumorale verabreichung nackter il-12 codierender nukleinsäuremoleküle
CY1108706T1 (el) Ανοσορυθμιστης
CO6612174A2 (es) L-asparaginasa tratada con peg
ATE513843T1 (de) Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
EA200870366A1 (ru) Короткая внутренне сегментированная интерферирующая рнк
EA200870528A1 (ru) Композиции и способы ингибирования экспрессии гена pcsk9
DE60143901D1 (de) Antisense-modulation der clusterinexpression
NO20031129D0 (no) Varianter av human koagulasjonsfaktor VII
DK2219031T3 (da) Anvendelse af leptin til behandling af human lipoatrofi og fremgangsmåde til bestemmelse af prædisposition for behandlinngen
DE10290072D2 (de) Modulare Transfektionssysteme
ATE234835T1 (de) Trovafloxacin enhaltende suspensionen zur oralen anwendung
WO2004019893A3 (en) Modulators of angiogenesis
Guo et al. Lentivirus‐mediated microRNA‐26a‐modified neural stem cells improve brain injury in rats with cerebral palsy
CY1108552T1 (el) Θεραπευτικη αντιμετωπιση της μη αλκοολικης στεατοηπατιτιδας (nash)
DE60144525D1 (de) Des protein (igfbp)-2-oligodeoxynukleotide zur behandlung von prostatakrebs
CN101448847A (zh) 影响磷酸二酯酶表达的寡核苷酸
DE60206499D1 (de) Verfahren zur herstellung von d-pantothensäure und/oder salzen davon
BR0013228A (pt) Método e composições utilizados para modulação de angiogenese usando proteìna quinase raf e ras
MX2023005154A (es) Nanopartículas codificadas de adn y método de uso de las mismas como una vacuna contra la enfermedad corona virus (covid-19).
ATE500840T1 (de) Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort
ITMI20030860A1 (it) Metodo per l'inibizione selettiva del gene n-myc